

www.phoenixnestbiotech.com

# Phoenix Nest inc

Finding treatments for families.

ASGCT
May 10<sup>th,</sup> 2021
Patient Advocates'
Role in Advancing Gene
Therapy

#### When a pharma executive tells you:


"Your disease is so rare I wouldn't touch it with a ten-foot pole."

There are three things you can do:

Sink, **Swim** or Tread-Water.

### If you decide to swim, you'll need:

- Shark repellant- Thick skin
- A Kickboard- Funding
- Life jacket- Partners



Session 2 –Understanding the research process: Being equipped for success

#### 'Building a successful partnership'

**Partner:** any number of individuals with interests and investments in a business or enterprise, among whom expenses, profits, and losses are **shared.** 

#### **Partners:**

- NIH Partner
- Business Partners
- Advocacy Partners
- KOL's
- Sympathetic Partners
- Clinical Partners
- Research & Manufacturing
- FDA

#### **Top 3 Partnerships:**

#1 Life Partner

**#2 Patient Partners** 

#3 Academic Partners




# Life Partner or significant other as partners

For better, or worse, for richer, or poorer, in sickness and in health, to love and to cherish, until death do us part.

### Who can you depend on to help?

- Financial strain
- Business travel
- Child-care

- Stress
- Depression
- Commiserate





### Patient Families as Partners

**H.A.N.D.S.** – a consortium of like-minded parents

We're like The Avengers- as a TEAM we are:

More **Powerful** in Numbers.

Heroes, no child is left behind.

Co-workers, we **share** the workload.

Global, everywhere at once.

Smarter, more skill sets

Not alone




















# Academics as Partners


- Experts in your disease
- Generate treatment ideas
- Publications
- Grant applications

### Academic researchers come with Strings- INSTITUTIONS

- Contracts
- I.P. considerations
- Royalty negotiations
- Delays












## NIH as a Partner Highly Recommended

- Funding Source (my kickboard)
- Knowledge and Advice
- In house resources







Jill Morris

\*1R41HD092110-01 Award Amount: \$225,000.00

Structure-based optimization of a novel pharmacological chaperone for MPS

\*1R41NS092221-01 Award Amount: \$224,469

Engineering stem cells to make mucopolysaccharidosis IIIB

\*1R42NS089061-01 Award Amount: \$223,102

Development and in vitro validation of therapy for mucopolysaccharidosis IIID

\*2R42NS089061-02 & 03 Award Amount: \$1,495,008

Development and validation of therapy for mucopolysaccharidosis IIID

\*2U44NS089061-04 & 05 Award Amount: \$5,612,276

Development and validation of therapy for mucopolysaccharidosis IIID

Q Mute ✓









Monthly calls with NIH Grant Managers.


Business Partnerships

'It isn't personal it's just business'

This saying does not apply here.

When forming a biotechout of **desperation**:

- Own your company
- Hire an administrator
- Outsource



#### Advocacy Partners

Aligned Goals & Shared Resources

#### **Collaborating:**

- Newborn screening
- Patient Registry
- Funding research
- Connecting with families
- Rare disease legislation and public policy

H.A.N.D.S.

The National MPS Society

The EveryLife Foundation

The Cure Sanfilippo Foundation





### Key Opinion Leaders as Partners

#### Who are your KOL's?

- Pharma Executives
- Researchers
- Clinicians
- Seasoned Patient Advocates

#### What can they do for you?

- Offer advice
- Sounding board
- Make introductions
- Point you in the right direction
- Advocate for you
- Give you credibility



#### Sympathetic Partners

Anybody that will give their **services** for free or at a great discount.

- Foundations founded by CEO's
- Members of Congress
- Accountants & Lawyers
- Consultants: CMC Experts, Regulatory,

Clinical

Medical & Grant writers



Research and Manufacturing

Companies as Partners (CRO and CMO)

Keep your researchers as consultants!

#### A company for every need:

- Regulatory help
- Animal studies
- Assay development
- Plasmid & Vector production
- Statisticians
- Medical writing

#### Benefits of CMO/CRO over Academia:

- Regular updates
- No IP or royalty negotiations
- Timely
- Cost effective
- Professional



Shout out to Jameson & Company: An outsourced accounting for government grants and contracts

#### Clinical Partners

If your goal is an interventional trial

#### Qualities to look for:

- They WANT to do it
- Reliable
- Progressive IRB
- Resources and Expertise



#### The FDA as a Partner

#### Phoenix Nest Pre-IND meetings

- CDER April 2019 Type B meeting
- CBER July 2019 Type B meeting

#### **Accessibility?**

- Response Time
- Response.

#### **Attention?**

- Slowly Progressing
- No approved biomarker
- Lack of Natural History
- Tiny patient population

#### **Assurance?**

- Guidance's
- Goal posts

#### Attainable?

- Realistic goals
- Right endpoints

# Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry

Additional copies are available from:

Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: druginfo@fda.hhs.gov
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

and/or

#### Contains Nonbinding Recommendations

ressive, Low-Prevalence Rare Diseases Wi sition That Result From Single Enzyme Do Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry<sup>1</sup>



Contact me at: jwood@phoenixnestbiotech.com